Analysts Set Tyra Biosciences, Inc. (NASDAQ:TYRA) Target Price at $47.00

Tyra Biosciences, Inc. (NASDAQ:TYRA) has earned a consensus rating of “Moderate Buy” from the fifteen analysts that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, twelve have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $47.00.

Several analysts have weighed in on TYRA shares. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of Tyra Biosciences in a report on Thursday, May 14th. JonesTrading began coverage on Tyra Biosciences in a report on Wednesday, June 17th. They set a “buy” rating and a $56.00 price objective for the company. Wolfe Research assumed coverage on shares of Tyra Biosciences in a research report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Bank of America raised their target price on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Finally, Piper Sandler lifted their target price on shares of Tyra Biosciences from $42.00 to $56.00 and gave the company an “overweight” rating in a research report on Friday, March 20th.

Institutional Trading of Tyra Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Hilton Head Capital Partners LLC purchased a new position in Tyra Biosciences in the first quarter worth $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in Tyra Biosciences during the fourth quarter valued at about $51,000. Chung Wu Investment Group LLC purchased a new stake in Tyra Biosciences during the fourth quarter valued at about $53,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Tyra Biosciences by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock worth $68,000 after purchasing an additional 534 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Tyra Biosciences by 14.5% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after purchasing an additional 1,668 shares during the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Stock Performance

Shares of TYRA stock opened at $32.88 on Friday. Tyra Biosciences has a 52-week low of $9.96 and a 52-week high of $40.65. The company has a market capitalization of $1.96 billion, a PE ratio of -15.08 and a beta of 0.76. The business’s fifty day moving average is $31.26 and its 200 day moving average is $32.30.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). On average, sell-side analysts forecast that Tyra Biosciences will post -2.68 EPS for the current fiscal year.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.